Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
← catalyst calendarNCT04588922 · readout in 133 d
Sponsored by Sellas Life Sciences Group (industry) · SLS — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
160estimated
Sites
26
Countries
China, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-10 | actual | When the study began enrolling |
| Primary completion | 2026-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hematologic Malignancies
Interventions
- Drug: SLS009 — also filed as GFH009
- Drug: venetoclax — also filed as Venclexta
- Drug: azacitidine — also filed as Vidaza, azacytidine
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability: Dose Limiting Toxicities (DLTs)
measured 21 to 28 days
Safety and Tolerability: adverse events (AEs)
measured approximately 2 years
Efficacy: ORR
measured 2 years
Permalink · SLS's whole pipeline · Catalyst calendar · Every registered study · What changed